Swapnil Shah
#804Managing Director
39
Age
18y
Exp
8y
Tenure
5/10
Risk
🎓 B.E. Chemical Engineering · Nirma University
📜 MBA · Hofstra University, New York
🏛️ None
CompensationTBP
Personality
5
Open
6
Cons
4
Extr
5
Agre
4
Neur
Senores Pharma.
Healthcare · Small Cap
Early Growth · Founder-Centric
About
Swapnil Shah is the Managing Director of Senores Pharma., a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Pragmatic leader with 18 years of experience, he is known for data-driven decision-making and organic builder strategy. Focuses on niche pharmaceutical segment growth and steady scaling of R&D capabilities for export markets.
FAQ
What is Swapnil Shah's leadership style?
Swapnil Shah is classified as a Pragmatic leader. He is data-driven in decision-making, with a category creator motivation and startup-speed pace of execution.
What is Swapnil Shah's educational background?
Swapnil Shah holds a B.E. Chemical Engineering from Nirma University and a MBA from Hofstra University, New York.
Who is the CEO of Senores Pharma.?
Swapnil Shah is the Managing Director of Senores Pharma.. He has been with the company for 8 years and in the current role for 8 years.
Leadership DNA
ArchetypePragmatic
MotivationCategory Creator
CrisisSteady Hand
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandValue-Champion
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Focuses on niche pharmaceutical segment growth and steady scaling of R&D capabilities for export markets.”
⚡ Crisis●●●○○
As a pragmatic leader in the highly regulated pharmaceutical sector, he prioritizes operational stability and compliance over reactive restructuring.
🎯 Motivation●●●○○
His focus on product innovation at Senores Pharma indicates a drive to develop niche, high-value pharmaceutical formulations rather than mere volume expansion.
👥 People●●●●○
His documented management style is explicitly defined by a data-driven approach, relying on analytical metrics to guide corporate decision-making.
📈 Growth●●●○○
His leadership emphasizes internal product development and innovation cycles as the primary engine for Senores Pharma's growth.
💡 Innovation●●●●○
The company focuses on high-growth therapeutic segments like critical care and anesthesia by leveraging a portfolio of established, off-patent pharmaceutical products.
🏃 Pace●●●●○
The company has demonstrated aggressive expansion in its product portfolio and geographic footprint since its recent IPO, characteristic of a high-growth small-cap entity.
🌱 Purpose●●●○○
As a small-cap pharmaceutical player in the early growth phase, its primary strategic focus is on rapid revenue scaling and market penetration rather than ESG-led initiatives.
🏷️ Brand●●●●○
The company positions itself as a provider of affordable, high-quality essential medicines and critical care solutions, competing effectively on cost and accessibility.
🤝 Customer●●●●●
The company operates primarily as a B2B manufacturer supplying hospitals, clinics, and institutional procurement channels with critical care products.
💼 Employer●●●○○
The high-growth, founder-led nature of the firm in a competitive, regulated sector implies a performance-oriented culture with aggressive operational targets.
📋 Mandate
As a niche pharmaceutical entrant, the company needs a visionary leader to drive R&D differentiation and capture market share in competitive therapeutic segments.
🏢 Culture●●●○○
Early-growth stage firm with strong promoter involvement; strategy and operational execution are heavily tied to the founding leadership.
Financials
Revenue FY25₹383 Cr
PAT FY25₹59 Cr
Rev CAGR 5Y200.8%
OPM19%
NPM15.3%
ROE7.4%
ROCE7.4%
P/E28.2
Fwd P/E23
P/B4.4
D/E28.9
Promoter56.7%
Institutional7.7%
Mkt Cap₹3K Cr
Compensation
To Be Published
Data being verified from audited reports
